Affordable Access

deepdyve-link
Publisher Website

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Authors
  • Kamat, Ashish M1
  • Bellmunt, Joaquim2
  • Galsky, Matthew D3
  • Konety, Badrinath R4
  • Lamm, Donald L5
  • Langham, David6
  • Lee, Cheryl T7
  • Milowsky, Matthew I8
  • O'Donnell, Michael A9
  • O'Donnell, Peter H10
  • Petrylak, Daniel P11
  • Sharma, Padmanee12
  • Skinner, Eila C13
  • Sonpavde, Guru14
  • Taylor, John A 3rd15
  • Abraham, Prasanth12
  • Rosenberg, Jonathan E16
  • 1 University of Texas MD Anderson Cancer Center, 1515 Pressler Unit 1373, Houston, TX, 77030, USA. [email protected]
  • 2 Dana-Farber Cancer Institute, Brookline, MA, 02446, USA.
  • 3 Tisch Cancer Institute at Mount Sinai Medical Center, New York, NY, 10029, USA.
  • 4 University of Minnesota, Minneapolis, MN, 55455, USA.
  • 5 BCG Oncology, Phoenix, AZ, 85032, USA.
  • 6 Bladder Cancer Advocacy Network, North Carolina Triangle Chapter, Chapel Hill, NC, 27517, USA.
  • 7 The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
  • 8 University of North Carolina, Chapel Hill, NC, 27599, USA.
  • 9 University of Iowa, Iowa City, IA, 52242, USA.
  • 10 University of Chicago, Chicago, IL, 60637, USA.
  • 11 Yale Cancer Center, New Haven, CT, 06520, USA.
  • 12 University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • 13 Stanford University, Stanford, CA, 94305, USA.
  • 14 University of Alabama, Birmingham, AL, 35294, USA.
  • 15 University of Kansas Cancer Center, Kansas City, KS, 66160, USA.
  • 16 Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Sep 28, 2017
Volume
5
Issue
1
Pages
80–80
Identifiers
DOI: 10.1186/s40425-017-0280-z
PMID: 28962591
Source
Medline
License
Unknown
Report this publication

Statistics

Seen <100 times